10:39 AM EDT, 05/30/2024 (MT Newswires) -- Avita Medical ( RCEL ) said Thursday that the US Food and Drug Administration has approved its premarket approval supplement for its cell harvesting device, Recell Go, for the treatment of thermal burn wounds and partial and full-thickness wounds.

The regenerative medicine company said it plans to launch Recell Go at US burn centers in June, with existing accounts transitioning throughout the year and new accounts to receive Recell Go from the start.

Shares of Avita Medical ( RCEL ) were up 6.4% in recent trading.

Price: 9.37, Change: +0.56, Percent Change: +6.36